22
02, 2019
14
02, 2019
Lorenza Rimassa et al., Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition
Diatech Pharmacogenetics2020-01-22T12:34:31+01:00
5
02, 2019
3
02, 2019
16
01, 2019
4
12, 2018
4
12, 2018
15
11, 2018
15
11, 2018
9
11, 2018